tirzepatide review article The promise of tirzepatide: A narrative of metabolic benefits Cardiovascular outcomes of semaglutide and

HWR reports receiving research support for clinical trials, service as principal investigator, on advisory boards, speaking and consulting from Eli Lilly and Co, Esperion, Bayer, Boehringer Ingelheim, Novo Nordisk, Sanofi, and Zealand

If pregnant, breastfeeding, or currently taking medication, consult a healthcare professional before use

What happens when you stop taking tesamorelin

JAMA Data Brief: GLP-1 receptor agonist use among US adults with type 2 diabetes nearly doubled between 2019 and 2022, primarily driven by semaglutide and dulaglutide

PA PMHNPs will need physician backup to prescribe GLP-1s

* Correspondence: Junlin Lu [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers